Recently, NewDEL Biotech stood out among over 3,000 companies and made it to the Top 150 of the 2022 ChinaVenture 50 "New Seed List"!

Venture50 is an enterprise selection based on investment dimensions, aimed at gathering the strength of venture capital to promote the development of innovation and entrepreneurship in China and discover future unicorn enterprises. The list, which has evolved over more than a decade, serves as a benchmark for high-growth enterprise investment. 2022 marks the 17th year of the ClearState Venture50 selection, with both the "Storm List" and "New Shoots List" TOP50 being set. Among them, companies selected for the New Shoots List are those that have received financing up to Series B and were established after 2019 but are not yet listed. After six months of careful comparison and scoring by judges, 150 enterprise projects were selected from over 3,000 companies to enter the initial selection list of the 2022 Venture50 New Shoots List, witnessing the strength of the industry together.

About Venture50

Founded by ClearState Entrepreneurship in 2006, Venture50 has accompanied numerous high-quality enterprises to be discovered and noticed over the years, witnessing countless outstanding entrepreneurial enterprises grow from "new shoots" to "unicorns". As of October 2022, the Venture50 event has accumulated over 70,000 participating enterprises, helping them raise over $35.8 billion in financing. The follow-up financing rate of V50-listed enterprises in the past three years reached 61%, with an IPO rate of approximately 27.8%. 2022 marks the 17th year of the Venture50 selection, with both the "Storm List" and "New Shoots List" TOP50 being set again.

About NewDEL Biotech

Established in April 2021, Shenzhen Shenzhen NewDEL Biotech Co., Ltd. is the first biopharmaceutical company incubated by the Guangdong Innovation Center For Small Molecule Drug Discovery. Leveraging independently-owned DEL 3.0 library construction and unique live cell screening technology, NewDEL Biotech focuses on unmet clinical needs, establishing an innovative drug lifecycle system focused on FIC innovative drug design, research and development, and industrialization. The company is committed to becoming an internationally leading, distinctly characterized R&D-oriented biopharmaceutical company.